Tweetovi

Blokirali ste korisnika/cu @antonynewton001

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @antonynewton001

  1. proslijedio/la je Tweet
    13. sij

    We’re excited to be at the Advances in Liquid Biopsies conference. Please get in touch if you would like to meet our medical team and hear more about our platform and our test relevant to the care of patients with advanced

    Poništi
  2. proslijedio/la je Tweet
    31. lis 2019.

    Nitzan Rosenfeld, CSO and co-founder of Inivata, describes the impact of on his family life and the personal motivations behind his work developing pioneering technology. Read the full interview here

    Poništi
  3. proslijedio/la je Tweet
    30. lis 2019.

    This is a Pfizer-funded study for but same study methodology could be applied to look at to other targeted therapies in onocology, says . CEO. Ramp up in these deals expected over next 12 months.

    Poništi
  4. proslijedio/la je Tweet
    29. lis 2019.
    Poništi
  5. 29. lis 2019.

    Invision First-Lung Liquid Biopsy Test selected by EORTC for a Pfizer funded trial of lorlatinib. Use for selection and monitoring will help understanding of resistance and inform future strategies for combination therapy.

    Poništi
  6. proslijedio/la je Tweet
    23. lis 2019.

    Our VP of Business Development speaking at the Precision Lung Cancer Summit on the platform and how its high sensitivity can assist in areas such as enrolling patients for trials and the early identification of response

    Poništi
  7. proslijedio/la je Tweet
    23. lis 2019.

    Earlier today Inivata’s presented on the sensitivity of the platform - recently we shared data showing how the platform could also help predict patient response to immune checkpoint inhibitors in - read more:

    Poništi
  8. proslijedio/la je Tweet
    14. lis 2019.

    Going to the Precision Lung Cancer Summit 2019 next week? So are we! We’re always interested in hearing about opportunities for collaboration and partnering with our platform. More info here

    Poništi
  9. proslijedio/la je Tweet
    9. lis 2019.

    leader and collaborators at and Research Center of Toulouse (CRCT) have published a novel approach to predicting patient response to in advanced non-small cell .

    Poništi
  10. proslijedio/la je Tweet
    8. lis 2019.

    Pleased to have published a new approach predicting patient response to immune checkpoint inhibitors in advanced NSCLC in the Lung Cancer journal with University of Toulouse and

    Poništi
  11. proslijedio/la je Tweet
    8. lis 2019.

    Novel approach based on our InVision® liquid biopsy platform identifies NSCLC patients who are most likely to respond to treatment with PD1 inhibitors. Read more here

    Poništi
  12. proslijedio/la je Tweet
    28. ruj 2019.

    Presenting new data . Together with our valued collaborators we are transforming clinical cancer care with

    Poništi
  13. proslijedio/la je Tweet
    28. ruj 2019.

    Emma from our clinical team and Tony from BD busy at this weekend. If you’d like to meet with the team, please let us know

    Poništi
  14. proslijedio/la je Tweet

    This year recognized Eniko Papp Ph.D to reflect the high quality of research she has completed. Very proud!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·